Last reviewed · How we verify

Paul Di Cesare,MD — Portfolio Competitive Intelligence Brief

Paul Di Cesare,MD pipeline: 1 marketed, 0 filed, 0 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

1 marketed 0 filed 0 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
Fondaparinux Sodium (Arixtra) Fondaparinux Sodium (Arixtra) marketed Factor Xa inhibitor Factor Xa Cardiovascular

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Baim Institute for Clinical Research · 1 shared drug class
  2. Bayer · 1 shared drug class
  3. Bristol-Myers Squibb · 1 shared drug class
  4. China National Center for Cardiovascular Diseases · 1 shared drug class
  5. GlaxoSmithKline · 1 shared drug class
  6. Hoffmann-La Roche · 1 shared drug class
  7. Kim, Seok Jin · 1 shared drug class
  8. NYU Langone Health · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Paul Di Cesare,MD:

Cite this brief

Drug Landscape (2026). Paul Di Cesare,MD — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/paul-di-cesare-md. Accessed 2026-05-16.

Related